- Home
- HIG vs INSM Comparison
HIG vs INSM Comparison
Compare HIG & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIG | INSM |
|---|---|---|
| Founded | 1810 | 1988 |
| Country | United States | United States |
| Employees | 19200 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.3B | 30.1B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | HIG | INSM |
|---|---|---|
| Price | $138.73 | $153.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 24 |
| Target Price | $149.38 | ★ $200.48 |
| AVG Volume (30 Days) | 1.1M | ★ 2.3M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.06 | $177.03 |
| Revenue Next Year | $4.13 | $66.55 |
| P/E Ratio | $10.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $113.27 | $63.81 |
| 52 Week High | $143.98 | $212.75 |
Technical Indicators
Market Signals| Indicator | HIG | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 55.32 | 50.19 |
| Support Level | $129.04 | $136.24 |
| Resistance Level | $139.25 | $166.81 |
| Average True Range (ATR) | 2.46 | 6.16 |
| MACD | 0.61 | -0.04 |
| Stochastic Oscillator | 70.91 | 52.27 |
Price Performance
Historical ComparisonAbout HIG Hartford Financial Services Group Inc. (The)
The Hartford Insurance Group Inc. provides property and casualty insurance, group benefits, and mutual funds. The company is widely recognized for its service excellence, sustainability practices, trust, and integrity. The Company currently conducts business principally in five reportable segments, including Business Insurance, Personal Insurance, Property & Casualty Other Operations, Employee Benefits, and Hartford Funds, as well as a Corporate category. The company generates a majority of its revenue from Business Insurance.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.